P517: SURVIVAL OUTCOMES WITH CPX-351 VS 7 + 3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK OR SECONDARY ACUTE MYELOID LEUKEMIA: A 5-YEAR FOLLOW-UP STUDY

• Ellen Ritchie,
• Tara L. Lin,
• Laura F. Newell,
• Robert K. Stuart,
• Scott Solomon,
• Richard Stone,
• Gary Schiller,
• Matthew Wieduwilt,
• Eileen Amy Ryan,
• Nalina Dronamraju,
• Jeffrey Lancet,
• Jorge Cortes

Affiliations

Ellen Ritchie

1 Weill Cornell Medicine, The New York Presbyterian Hospital, New York, NY, United States

Tara L. Lin

2 University of Kansas Medical Center, Kansas City, KS, United States

Laura F. Newell

3 Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, United States

Robert K. Stuart

4 Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States

Scott Solomon

5 Northside Hospital Cancer Institute, Atlanta, GA, United States

Richard Stone

6 Dana-Farber Cancer Institute, Boston, MA, United States

Gary Schiller

7 David Geffen School of Medicine at UCLA, Los Angeles, CA, United States

Matthew Wieduwilt

8 Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, United States

Eileen Amy Ryan

9 University of Rochester, Rochester, New York, NY, United States

Nalina Dronamraju

10 Jazz Pharmaceuticals, Philadelphia, PA, United States

Jeffrey Lancet

11 H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States

Jorge Cortes

12 Georgia Cancer Center, Augusta University, Augusta, GA, United States